Docoh
Loading...

NEWH NewHydrogen

Filed: 24 Feb 21, 3:55pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 18, 2021

 

BIOSOLAR, INC.

(Exact name of registrant as specified in its charter)

 

Nevada 000-54819 20-4754291
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation)   Identification No.)

 

27936 Lost Canyon Road, Suite 202, Santa Clarita, CA 91387

(Address of principal executive offices and Zip Code)

 

Registrant’s telephone number, including area code: (661) 251-0001

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:      

 

Title of each class Ticker symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 18, 2021 the board of directors of BioSolar, Inc. (the “Company”) granted David Lee an option to purchase 400,000,000 shares of the Company’s common stock. Half of the Option is immediately exercisable and the remaining half of the Option will become vested and exercisable on a monthly basis over two years with the first vesting on March 18, 2021, and shall be exercisable at a price of $0.091.

 

On February 18, 2021 the board of directors of BioSolar, Inc. (the “Company”) granted Spencer Hall an option to purchase 50,000,000 shares of the Company’s common stock and will become vested and exercisable on a monthly basis over three years with the first vesting on March 18, 2021, and shall be exercisable at a price of $0.091.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibits
Number
 Description
3.1   

Nonstatutory Stock Option Agreement between David Lee and the Company dated February 18, 2021

   
3.2 Nonstatutory Stock Option Agreement between Spencer Hall and the Company dated February 18, 2021

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 BIOSOLAR, INC.
  
Date: February 24, 2021/s/ David Lee
 David Lee
 Chief Executive Officer

 

 

2